International, Multicentre, Observational, Prospective, Longitudinal Study to Assess the Effectiveness of AboBoNT-A Injections for Adult Lower Limb Spasticity in a Real Life Cohort (AboLiSh)
Latest Information Update: 04 Jun 2024
Price :
$35 *
At a glance
- Drugs Botulinum-Toxin-A (Primary)
- Indications Muscle spasticity
- Focus Therapeutic Use
- Acronyms AboLiSh
- Sponsors Ipsen
- 18 Apr 2024 Top line results assessing effectiveness of Abobotulinumtoxin A in Adults with Lower Limb Spasticity, presented at the 76th Annual Meeting of the American Academy of Neurology 2024
- 14 Dec 2022 According to Ipsen media release, the company has presented the data from this study in the 12th World Congress for Neurorehabilitation (WCNR).
- 04 Aug 2022 Status changed from active, no longer recruiting to completed.